Literature DB >> 19188375

In vitro activities of fluconazole and voriconazole against clinical isolates of Candida spp. determined by disk diffusion testing in Turin, Italy.

Narcisa Mandras1, Vivian Tullio, Valeria Allizond, Daniela Scalas, Giuliana Banche, Janira Roana, Francesca Robbiano, Giacomo Fucale, Aurelio Malabaila, Anna Maria Cuffini, Nicola Carlone.   

Abstract

The in vitro activities of fluconazole and voriconazole against 1,024 clinical isolates of Candida spp. were determined by the agar disk diffusion test using the Clinical and Laboratory Standards Institute (CLSI) M44-A guidelines. The results of this investigation demonstrated the broad-spectrum in vitro activity of voriconazole, relative to that of fluconazole, against yeasts tested, in particular fluconazole-resistant isolates, such as Candida krusei that showed high susceptibility to voriconazole. The situation in Turin, Italy, is quite similar to that of the rest of Italy, reflecting the worldwide trend.

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19188375      PMCID： PMC2663129          DOI： 10.1128/AAC.00998-08

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  17 in total

1.  Guidelines for treatment of candidiasis.

Authors:  Peter G Pappas; John H Rex; Jack D Sobel; Scott G Filler; William E Dismukes; Thomas J Walsh; John E Edwards
Journal:  Clin Infect Dis       Date:  2003-12-19       Impact factor: 9.079

2.  Candida kefyr as an emerging pathogen causing nosocomial bloodstream infections in neutropenic leukemia patients.

Authors:  Christoph W M Reuter; Michael A Morgan; Franz-Christoph Bange; Florian Gunzer; Matthias Eder; Bernd Hertenstein; Arnold Ganser
Journal:  Clin Infect Dis       Date:  2005-11-01       Impact factor: 9.079

3.  In vitro activities of voriconazole, fluconazole, itraconazole and amphotericin B against non Candida albicans yeast isolates.

Authors:  Danielle Swinne; Mirjam Watelle; Nicole Nolard
Journal:  Rev Iberoam Micol       Date:  2005-03       Impact factor: 1.044

4.  Results from the ARTEMIS DISK Global Antifungal Surveillance Study: a 6.5-year analysis of susceptibilities of Candida and other yeast species to fluconazole and voriconazole by standardized disk diffusion testing.

Authors:  M A Pfaller; D J Diekema; M G Rinaldi; R Barnes; B Hu; A V Veselov; N Tiraboschi; E Nagy; D L Gibbs
Journal:  J Clin Microbiol       Date:  2005-12       Impact factor: 5.948

5.  Fluconazole-resistant pathogens Candida inconspicua and C. norvegensis: DNA sequence diversity of the rRNA intergenic spacer region, antifungal drug susceptibility, and extracellular enzyme production.

Authors:  Takashi Sugita; Kanji Takeo; Misako Ohkusu; Eric Virtudazo; Masako Takashima; Emi Asako; Fumiko Ohshima; Satoshi Harada; Chikako Yanaka; Akemi Nishikawa; Laszlo Majoros; Matthias Sipiczki
Journal:  Microbiol Immunol       Date:  2004       Impact factor: 1.955

Review 6.  Non-albicans Candida spp. causing fungaemia: pathogenicity and antifungal resistance.

Authors:  V Krcmery; A J Barnes
Journal:  J Hosp Infect       Date:  2002-04       Impact factor: 3.926

7.  A global evaluation of the susceptibility of Candida species to fluconazole by disk diffusion. Global Antifungal Surveillance Group.

Authors:  J Meis; M Petrou; J Bille; D Ellis; D Gibbs
Journal:  Diagn Microbiol Infect Dis       Date:  2000-04       Impact factor: 2.803

8.  Comparison of the susceptibilities of Candida spp. to fluconazole and voriconazole in a 4-year global evaluation using disk diffusion.

Authors:  Kevin C Hazen; Ellen Jo Baron; Arnaldo Lopes Colombo; Corrado Girmenia; Aurora Sanchez-Sousa; Amalia del Palacio; Catalina de Bedout; David L Gibbs
Journal:  J Clin Microbiol       Date:  2003-12       Impact factor: 5.948

9.  Antifungal susceptibility survey of 2,000 bloodstream Candida isolates in the United States.

Authors:  Luis Ostrosky-Zeichner; John H Rex; Peter G Pappas; Richard J Hamill; Robert A Larsen; Harold W Horowitz; William G Powderly; Newton Hyslop; Carol A Kauffman; John Cleary; Julie E Mangino; Jeannette Lee
Journal:  Antimicrob Agents Chemother       Date:  2003-10       Impact factor: 5.191

10.  In vitro fluconazole susceptibility of 1565 clinical isolates of Candida species evaluated by the disk diffusion method performed using NCCLS M44-A guidelines.

Authors:  Gian Piero Testore; Luca Dori; Anna Rita Buonomini; Gian Carlo Schito; Ornella Soro; Giacomo Fortina; Stefano Andreoni; Nicola Carlone; Vivian Tullio; Massimo Andreoni
Journal:  Diagn Microbiol Infect Dis       Date:  2004-11       Impact factor: 2.803
View more
  8 in total

1.  Fluorescent Capillary Electrophoresis Is Superior to Culture in Detecting Candida Species from Samples of Urinary Catheters and Ureteral Stents with Mono- or Polyfungal Biofilm Growth.

Authors:  Hana Obručová; Iva Kotásková; Radka Tihelková; Veronika Holá; Filip Růžička; Tomáš Freiberger
Journal:  J Clin Microbiol       Date:  2019-03-28       Impact factor: 5.948

Review 2.  Pharmacokinetics and pharmacodynamics of antibacterials, antifungals, and antivirals used most frequently in neonates and infants.

Authors:  Jessica K Roberts; Chris Stockmann; Jonathan E Constance; Justin Stiers; Michael G Spigarelli; Robert M Ward; Catherine M T Sherwin
Journal:  Clin Pharmacokinet       Date:  2014-07       Impact factor: 6.447

3.  Upregulation of secreted aspartyl proteinase genes of fluconazole-sensitive Candida albicans isolates.

Authors:  Carolina do Rosário Esteves Guimarães; Humberto Fonseca de Freitas; Tânia Fraga Barros
Journal:  Mol Biol Rep       Date:  2019-10-10       Impact factor: 2.316

4.  In vitro activity of five antifungal agents against Candida albicans isolates, Sari, Iran.

Authors:  T Shokohi; H Badali; N Amirrajab; M R Ataollahi; S A Kouhpayeh; M H Afsarian
Journal:  Curr Med Mycol       Date:  2016-06

5.  A comparative study on production of extracellular hydrolytic enzymes of Candida species isolated from patients with surgical site infection and from healthy individuals and their co-relation with antifungal drug resistance.

Authors:  Rakhshanda Erum; Farkhunda Samad; Adnan Khan; Shahana Urooj Kazmi
Journal:  BMC Microbiol       Date:  2020-12-03       Impact factor: 3.605

6.  Community acquired fungemia caused by Candida pulcherrima: diagnostic contribution of MALDI-TOF mass spectrometry.

Authors:  Laurène Deconinck; Agnès Meybeck; Maxime Pradier; Pierre Patoz; Hugues Melliez; Eric Senneville
Journal:  Ann Clin Microbiol Antimicrob       Date:  2016-03-08       Impact factor: 3.944

7.  Liquid and vapour-phase antifungal activities of essential oils against Candida albicans and non-albicans Candida.

Authors:  Narcisa Mandras; Antonia Nostro; Janira Roana; Daniela Scalas; Giuliana Banche; Valeria Ghisetti; Simonetta Del Re; Giacomo Fucale; Anna Maria Cuffini; Vivian Tullio
Journal:  BMC Complement Altern Med       Date:  2016-08-30       Impact factor: 3.659

8.  Prevalence of vulvovaginal candidiasis among pregnant women in the Ho municipality, Ghana: species identification and antifungal susceptibility of Candida isolates.

Authors:  Sayanika Devi Waikhom; Innocent Afeke; Grace Sefakor Kwawu; Hintermann Kobina Mbroh; George Yiadom Osei; Bengyella Louis; John Gameli Deku; Emmanuel Senyo Kasu; Prosper Mensah; Charles Yao Agede; Cornelius Dodoo; Emmanuel Akomanin Asiamah; John Tampuori; John Korbuvi; Japheth Awuletey Opintan
Journal:  BMC Pregnancy Childbirth       Date:  2020-05-06       Impact factor: 3.007
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.